OpenURL Connection Search

Select item for more details and to access through your institution.

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer.
Published in:
Investigational New Drugs, 2024, v. 42, n. 3, p. 261, doi. 10.1007/s10637-024-01422-6
By:
- Yamamoto, Noboru;
- Satouchi, Miyako;
- Doi, Toshihiko;
- Fujiwara, Yutaka;
- Yanagitani, Noriko;
- Kawa, Yoshitaka;
- Yoh, Kiyotaka;
- Leopold, Lance;
- Munteanu, Mihaela;
- Sawada, Takashi;
- Han, Shirong;
- Noguchi, Kazuo;
- Nishio, Makoto
Publication type:
Article
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
Published in:
Investigational New Drugs, 2024, v. 42, n. 1, p. 136, doi. 10.1007/s10637-023-01411-1
By:
- Nogami, Naoyuki;
- Tokito, Takaaki;
- Zenke, Yoshitaka;
- Satouchi, Miyako;
- Seto, Takashi;
- Saka, Hideo;
- Ohtani, Junko;
- Han, Shirong;
- Noguchi, Kazuo;
- Nishio, Makoto
Publication type:
Article
Long‐term follow‐up results from KEYNOTE‐041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.
Published in:
Journal of Dermatology, 2024, v. 51, n. 5, p. 632, doi. 10.1111/1346-8138.17002
By:
- Yokota, Kenji;
- Takenouchi, Tatsuya;
- Fujisawa, Yasuhiro;
- Fukushima, Satoshi;
- Uchi, Hiroshi;
- Inozume, Takashi;
- Kiyohara, Yoshio;
- Uhara, Hisashi;
- Nakagawa, Kazuhiko;
- Furukawa, Hiroshi;
- Han, Shirong;
- Watanabe, Masaru;
- Noguchi, Kazuo;
- Yamazaki, Naoya
Publication type:
Article
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775.
Published in:
Cancer Science, 2022, v. 113, n. 10, p. 3489, doi. 10.1111/cas.15436
By:
- Yonemori, Kan;
- Yunokawa, Mayu;
- Ushijima, Kimio;
- Sakata, Jun;
- Shikama, Ayumi;
- Minobe, Shinichiro;
- Usami, Tomoka;
- Enomoto, Takayuki;
- Takehara, Kazuhiro;
- Hasegawa, Kosei;
- Yamagami, Wataru;
- Yamamoto, Keiko;
- Han, Shirong;
- Dutta, Lea;
- Orlowski, Robert;
- Miura, Takuma;
- Makker, Vicky;
- Fujiwara, Keiichi
Publication type:
Article
Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer.
Published in:
Cancer Science, 2022, v. 113, n. 8, p. 2814, doi. 10.1111/cas.15462
By:
- Yamaguchi, Kensei;
- Minashi, Keiko;
- Sakai, Daisuke;
- Nishina, Tomohiro;
- Omuro, Yasushi;
- Tsuda, Masahiro;
- Iwagami, Shiroh;
- Kawakami, Hisato;
- Esaki, Taito;
- Sugimoto, Naotoshi;
- Oshima, Takashi;
- Kato, Ken;
- Amagai, Kenji;
- Hosaka, Hisashi;
- Komine, Keigo;
- Yasui, Hisateru;
- Negoro, Yuji;
- Ishido, Kenji;
- Tsushima, Takahiro;
- Han, Shirong
Publication type:
Article
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Published in:
Journal of Gynecologic Oncology, 2024, v. 35, n. 2, p. 1, doi. 10.3802/jgo.2024.35.e40
By:
- Kan Yonemori;
- Keiichi Fujiwara;
- Kosei Hasegawa;
- Mayu Yunokawa;
- Kimio Ushijima;
- Shiro Suzuki;
- Ayumi Shikama;
- Shinichiro Minobe;
- Tomoka Usami;
- Jae-Weon Kim;
- Byoung-Gie Kim;
- Peng-Hui Wang;
- Ting-Chang Chang;
- Keiko Yamamoto;
- Shirong Han;
- McKenzie, Jodi;
- Orlowski, Robert J.;
- Takuma Miura;
- Makker, Vicky;
- Yong Man Kim
Publication type:
Article

Found: 6

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer.

Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.

Long‐term follow‐up results from KEYNOTE‐041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775.

Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer.

Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.